Wedbush raised General Motors' (NYSE:GM) price target to $65 from $55, maintaining an 'Outperform' rating, citing the automaker's strategic management of tariff headwinds and a robust product pipeline as key growth drivers through 2026. Despite anticipating $4-5 billion in tariff-related costs impacting EBIT-adjusted and free cash flow, GM's $5 billion investment in cost efficiencies, potential trade deals, and a significant partnership with Hyundai for new vehicle development underscore its ability to navigate the complex economic environment and sustain demand across its fleet.
Wedbush has raised its price target for General Motors (GM) to $65 from $55, maintaining an 'Outperform' rating, signaling strong confidence in the company's forward-looking strategy. The upgrade is predicated on GM's adept management of significant tariff headwinds, which are anticipated to incur costs of $4 billion to $5 billion, directly impacting EBIT-adjusted and free cash flow metrics. Despite these near-term pressures, the firm highlights GM's proactive mitigation strategies, including potential production relocations and cost-saving initiatives supported by a newly announced $5 billion incremental investment plan. This capital is being allocated towards enhancing cost efficiencies and internal reallocations to improve returns. Further optimism stems from potential catalysts such as new US trade deals with Canada and Mexico, building on a recent agreement with South Korea. Long-term growth is underpinned by a robust product pipeline, most notably a strategic partnership with Hyundai to co-develop multiple vehicles, including a commercial van, with production expected to scale to 800,000 units annually. This, combined with stable demand across both its EV and internal combustion engine fleets, positions GM to navigate the complex environment and drive growth through 2026.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment